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a  b  s  t  r  a  c  t
Clenbuterol  is  an  oral  2-agonist  utilized  as  an  illicit substance  for performance-enhancement  or  weight
loss.  We  report  a case  of a 23-year-old  male  who  presented  with  anxiety  and  chest  tightness  after  inten-
tional  ingestion  of  5000  g of  clenbuterol  (125  times  the  recommended  adult  dose)  to lose weight.  His
electrocardiogram  showed  sinus  tachycardia  and  diffuse  nonspeciﬁc  repolarization  abnormalities  with
mild inferolateral  ST-segment  depression.  Bloodwork  revealed  a potassium  of  2.0  mmol/L,  peak  lactate
of 9.4  mmol/L,  and  peak  troponin  of 5.39 g/L. A transthoracic  echocardiogram  was  normal  except  for
hyperdynamic  left ventricular  function.  He was treated  with  intravenous  ﬂuids  and  oral  metoprolol.  His
tachycardia  and  electrocardiogram  abnormalities  resolved  after  48  h. Clenbuterol  has  gained  notoriety
in recent  years  as  a drug  of abuse  and  cases  of toxicity  will likely  continue  to  increase  due to  its  rela-
tive  attainability  and readily  accessible  online  dosing  information.  Patients  often  present  with agitation,
palpitations,  tachycardia,  hypokalemia,  and  hyperglycemia.  Treatment  is  supportive  with  intravenous
ﬂuids,  -blockers,  and  potassium  supplementation.
<Learning  objective:  Clenbuterol,  an  oral  2-agonist,  can  be utilized  as an  illicit substance  for
performance-enhancement  or  weight  loss.  Cardiac  toxicity  and  type  II myocardial  infarction  can
occur  with  clenbuterol  overdoses.  Associated  symptoms  include  agitation,  palpitations,  tachycardia,
hypokalemia,  and  hyperglycemia.  Treatment  is supportive  primarily  with  intravenous  ﬂuid,  -blockers,
and  potassium  supplementation.>
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Clenbuterol is a long-acting, oral 2-agonist primarily used as
n illicit substance for performance-enhancement or weight loss.
reviously published case reports of clenbuterol toxicity primarily
nvolved young male bodybuilders or the use of clenbuterol-
dulterated heroin by illicit drug users [1–6]. Clenbuterol toxicity
as also been reported with eating contaminated livestock [7].
lenbuterol toxicity often presents with tachycardia with or
ithout myocardial ischemia, as well as hypokalemia and hyper-
lycemia. Dyskinesias similar to those caused by neuroleptics,
ncluding tardive dyskinesia, have also been reported [5]. We
eport a case of unintentional clenbuterol cardiac toxicity resulting
n a presumptive type II myocardial infarction [8] after ingestion
f 5000 g for weight loss, which represents one of the highest
ingle-dose ingestions of clenbuterol identiﬁed in the published
iterature [6].∗ Corresponding author. Tel.: +1 780 407 7935; fax: +1 780 407 7690.
E-mail addresses: arden.barry@albertahealthservices.ca,
rden.barry@ualberta.ca (A.R. Barry).
878-5409/$ – see front matter © 2013 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jccase.2013.07.004anese  College  of Cardiology.  Published  by Elsevier  Ltd.  All  rights  reserved.
Case report
A 23-year-old male presented to the Emergency Department
with palpitations, anxiety, chest tightness, and shortness of breath
after intentional ingestion of clenbuterol two hours previously.
He ingested approximately 5000 g of clenbuterol (125 times the
recommended adult daily therapeutic dose of 40 g per day) [9]
with 750–1000 mL  of wine, in order to lose weight. The vial was
brought to hospital for positive identiﬁcation. He denied any inten-
tional self-harm or ingestion of other illicit substances. He was
not forthcoming with details regarding his dose selection or the
rationale for co-ingesting alcohol. His past medical history was non-
contributory except for nicotine dependence and he was not taking
any regular medications.
On presentation, the patient was  afebrile, diaphoretic, and
tachycardic [heart rate (HR) 160 bpm, blood pressure (BP)
115/55 mmHg]. His initial bloodwork is detailed in Table 1. He
described chest tightness, which resolved upon arrival, and he
had vomited before presentation to the hospital. His initial elec-
trocardiogram showed sinus tachycardia with mild inferolateral
ST-segment depression and diffuse nonspeciﬁc repolarization
abnormalities (Fig. 1). His ethanol level was 39 mmol/L and his
urine was  negative for cocaine and barbiturates. He was given intra-
venous ﬂuids with potassium supplementation, 1 mg  of sublingual
vier Ltd. All rights reserved.
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Table 1
Bloodwork.
Initial
Presentation
Day 1 Day 2
Serum potassium (mmol/L) 2.0 3.1 3.4
Serum glucose (mmol/L) 12.7 6.2 5.1
Serum lactate (mmol/L) 9.4 6.4 2.7
Troponin I (mcg/L) 0.43 1.31 5.39
Creatine kinase (U/L) 98 559 441
Hemoglobin (g/L) 152 - -
Serum magnesium (mmol/L) 0.62 - -
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iSerum creatinine (mol/L) 94 - -
Thyroid stimulating hormone (mU/L) 2.17 - -
orazepam, and 5 mg  of intravenous metoprolol. A clenbuterol
erum level was not measured. The cardiology service was con-
ulted after a troponin drawn 12 h after arrival was positive at
.43 g/L (normal <0.15 g/L). No seizures or cardiac arrhythmias
ere noted.
The patient was transferred to the coronary care unit for obser-
ation 17 h after his initial presentation. On arrival, he remained
emodynamically stable (HR 138 bpm, BP 122/47 mmHg). On
xamination, a mild tremor was noted. His pulses were bound-
ng but the remainder of his cardiac examination was otherwise
nremarkable. A repeat electrocardiogram was unchanged. A
ransthoracic echocardiogram demonstrated hyperdynamic left
entricular systolic function (ejection fraction >70%) but was  oth-
rwise normal. He was treated with metoprolol 25 mg  orally twice
aily, nicotine patch 7 mg  daily, and oral potassium chloride as
eeded. A cardioselective -blocker was chosen to reduce myocar-
ial ischemia due to increased demand. His tachycardia resolved
8 h post-clenbuterol ingestion. His troponin peaked at 5.39 g/L
nd his electrocardiogram subsequently normalized (Fig. 2). He
as discharged with approval 62 h after his initial presentation on
etoprolol 50 mg  orally twice daily for one week.iscussion
Clenbuterol is a long-acting, oral 2-adrenoceptor agonist
ndicated for the treatment of reactive airway diseases [9,10].
Fig. 1. Electrocardiogramrdiology Cases 8 (2013) 131–133
It is primarily utilized as a veterinary medication and is not
commercially available in most countries for human consumption.
The drug is similar in structure to salbutamol, although it is
more 2 selective, 100 times more potent, and has purported
anabolic properties (increased muscle mass and strength) [9–11].
It is rapidly and extensively absorbed after oral administration
with an onset of 30 min and bioavailability of 70–80% [9]. Peak
effect is often seen in 2–4 h with a therapeutic duration of 8–12 h.
Clenbuterol is both hepatically metabolized and renally excreted;
therefore, the elimination half-life (25–39 h) may  be prolonged in
patients with impaired renal function. The recommended adult
oral dose for the treatment of asthma is 20–40 g twice daily [9].
Clenbuterol has gained notoriety in recent years as a drug of
abuse. It is a banned substance by the International Olympic Com-
mittee and other professional sporting organizations. For the 2012
Olympic Games, China’s General Administration of Sport banned
its athletes from eating any type of meat products prior to the
games to avoid unintentional ingestion of clenbuterol. Several pro-
fessional athletes have tested positive for clenbuterol, including
Alberto Contador, a professional cyclist who  won the 2010 Tour
de France before being stripped of his title, and Guillermo Mota,
a Major League Baseball pitcher. The relative attainability of clen-
buterol (it is not a controlled substance by the US Food and Drug
Administration or Health Canada) and easily accessible online dos-
ing information has resulted in its abuse becoming more prevalent.
Recommendations regarding how to misuse “clen” or “angel dust”
(also slang for phencyclidine) for bodybuilding or weight loss
can be found on multiple internet blogs and social media web-
sites. Escalating societal demand for cosmetic-, appearance-, and
performance-enhancing substances will likely lead to an increased
number of cases involving clenbuterol toxicity in the future.
The clinical presentation of clenbuterol overdose is consistent
with that of other -agonists [9,10]. The differential diagnosis
includes thyrotoxicosis, pheochromocytoma, and benzodiazepine
withdrawal. Symptoms may  include agitation, tachycardia, palpita-
tions, and tremor. Laboratory derangements include hypokalemia
and hyperglycemia. More severe toxicity can present with seizures,
psychosis, myocardial infarction, ventricular arrhythmias, lactic
acidosis, or rhabdomyolysis. There is no role for clenbuterol
serum levels; however, all patients should also be tested for other
 on presentation.
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ubstances including cocaine, methamphetamines, and theo-
hylline (if a mixed or unknown overdose is suspected).
anagement of clenbuterol overdose is supportive care. There is no
ntidote. Sedatives or anxiolytics may  be used to treat agitation or
sychosis, and -blockers may  be administered in hemodynamic
ompromise or myocardial infarction as long as concomitant
ocaine ingestion has been ruled out. Hypokalemia is secondary to
ntracellular shift; therefore, supplementation should only be used
o correct critical values due to the risk of rebound hyperkalemia.
eizures can be treated with standard therapy, such as benzodi-
zepines. All patients should be assessed for potential self-harm.
bservation time is patient-speciﬁc based on the clinical presenta-
ion and degree of toxicity due to the long half-life of clenbuterol.
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